Immunotherapy-Based Regimen Efficacy/Safety Updates

Opinion
Video

Dr. Hammers discusses recent efficacy and safety data updates from CHECKMATE-214, KEYNOTE-426, and CHECKMATE-9ER trials.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Newsletter

      Stay up to date on practice-changing data in community practice.

      Subscribe Now!
      Recent Videos
      1 expert in this video
      Treatment Implementation and Long-Term Considerations in BPDCN
      Study Reveals Stark Disparities in RCC Clinical Trial Access Worldwide
      Study Reveals Stark Disparities in RCC Clinical Trial Access Worldwide
      Long-Term Data on IO/IO in RCC Shows Intriguing Results for Favorable Risk
      Long-Term Data on IO/IO in RCC Shows Intriguing Results for Favorable Risk
      Academic Perspectives on the Evolving Treatment Landscape in MPNs
      Academic Perspectives on the Evolving Treatment Landscape in MPNs
      1 expert in this video
      Adverse Events Monitoring and Management in BPDCN Treatment
      1 expert in this video
      Academic Perspectives on Treatment Decisions for BPDCN
      Quality of Life in MPNs: Patient-Centered Factors That Shape Treatment Approaches
      Quality of Life in MPNs: Patient-Centered Factors That Shape Treatment Approaches
      Advances in MPN Management: Insights From MANIFEST-2 and Beyond
      Advances in MPN Management: Insights From MANIFEST-2 and Beyond
      Ongoing studies of Ra-223–based combinations
      Ongoing studies of Ra-223–based combinations
      1 expert in this video
      Academic Perspectives on Systemic Therapy for Advanced uHCC
      Related Content
      Participants Explain Rationale for Different IO/TKI Options for ccRCC

      Participants Explain Rationale for Different IO/TKI Options for ccRCC

      Targeted Oncology Staff
      April 15th 2025
      Article

      During a live event, Daniel M. Geynisman, MD, and participants discussed their answers to a poll on which combination to use for a patient with advanced renal cell carcinoma.

      Read More

      Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC

      Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC

      Jordyn Sava;Peter Zang, MD
      March 1st 2024
      Podcast

      In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.

      Listen

      Reviewing Second-Line RCC Therapy After Immune Checkpoint Inhibition

      Reviewing Second-Line RCC Therapy After Immune Checkpoint Inhibition

      Targeted Oncology Staff
      April 10th 2025
      Article

      During a live event, Benjamin Garmezy, MD, discussed combinations regimens used for patients with renal cell carcinoma after immune checkpoint inhibitors.

      Read More

      Beyond the First-Line: Economides on Advancing Therapies in RCC

      Beyond the First-Line: Economides on Advancing Therapies in RCC

      Jordyn Sava;Minas P. Economides, MD
      February 1st 2024
      Podcast

      In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.

      Listen

      Reviewing RCC Treatment Choices After Progression With IO/TKI

      Reviewing RCC Treatment Choices After Progression With IO/TKI

      Targeted Oncology Staff
      March 27th 2025
      Article

      During a live event, Benjamin Garmezy, MD, discussed treatment options in renal cell carcinoma including IO/TKI combinations plus VEGF selectivity.

      Read More

      Peers Discuss Management of IO/TKI Toxicities and Dosing Strategies in Frontline RCC

      Peers Discuss Management of IO/TKI Toxicities and Dosing Strategies in Frontline RCC

      Targeted Oncology Staff
      March 11th 2025
      Article

      During a Case-Based Roundtable® event, Elizabeth M. Wulff-Burchfield, MD, and other participants discussed their experiences with the frontline combination regimens for advanced renal cell carcinoma.

      Read More